The Patent Finder

Guangzhou Sinogen Pharmaceutical Co., Ltd.

7 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2034
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 3, 2027
    The maintenance fee for Applications of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer (US 11,771,721) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

PatentTitleStatus Expires Confidence
US 9,816,083Genetically engineered bacterium for treatment of breast cancer, method for constructing the bacterium, and applications thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,439,934Application of an attenuated salmonella typhimurium, its genetically engineered bacterium in preparing drugs for the treatment of prostate cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,478,664Use of genetically engineered strain VNP20009-M in preventing and treating cancer metastasis
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,113,184Microbe transformant for weight loss and lipid reduction, the method for constructing the transformant, and application thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,318,172Use of genetically engineered bacterium of attenuated Salmonella typhimurium in for treating liver cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,324,781Application of genetically engineered bacteria VNP20009-M in preparing drug for treating malignant sarcoma
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,771,721Applications of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer
In force
 · From the USPTO record
In forceFrom the USPTO record

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited